Humacyte, JDRF to develop biovascular pancreas to treat type 1 diabetes

Humacyte (Nasdaq:HUMA) and JDRF announced today that they entered into a collaboration to develop a biovascular pancreas (BVP). The collaboration aims to advance the development of Humacyte’s BVP product candidate for treating type 1 diabetes. Humacyte designed its BVP to deliver insulin-producing islets using its investigational, tissue-engineered blood vessel. The company calls it the Human … Continue reading Humacyte, JDRF to develop biovascular pancreas to treat type 1 diabetes